Development and Applica0on of Real- Time Clinical Predic0ve Models

Similar documents
Learning Objec1ves. Study Design Considera1ons in Clinical Pharmacy

Learning Objec1ves. Study Design Strategies. Cohort Studies 9/28/15

Biosta's'cs Board Review. Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016

Economic outcomes: Method for implementa5on

Common Data Elements: Making the Mass of NIH Measures More Useful

Welcome! Pragmatic Clinical Studies. David Hickam, MD, MPH Program Director Clinical Effectiveness Research. David Hickam, MD, MPH

A review of approaches to identifying patient phenotype cohorts using electronic health records

Addressing the Challenge of Medica3on Adherence. Jan Berger MD, MJ President and CEO Health Intelligence Partners

Frailty in Geriatric Trauma Pa1ents

Identifying Engineering, Clinical and Patient's Metrics for Evaluating and Quantifying Performance of Brain- Machine Interface Systems

Department of Emergency Office of Research. Shannon McNabb, MA, MPH Clinical Research Manager January 2017

Chronic Kidney Disease

Findings from the At Home / Chez Soi Demonstration Project in Canada. Paula Goering and Catharine Hume May 2, 2013

A large database study in the general population in England

For more information about how to cite these materials visit

Engage and Empower Pa.ents with Interac.ve Technology. Northeast NAHAM Regional Conference Pa.ent Access: GeBng It Right Upfront October 22-23, 2012

2015 Na(onal Medicaid and CHIP Oral Health Symposium

Public Health / Public Works Introduc6on, reitera6on + Lessons 1-2. Pioneer Winter IDH 3034, IDH 4007

Heart Failure - Large Market Opportuni4es for New Biomarkers

Design, Conduct and Analysis of Pragma?c Clinical Trials in Pallia?ve Care Research

Leveraging the HSX Clinical Data Repository to Improve Behavioral Health Care:

3/31/2015. Designing Clinical Research Studies: So You Want to Be an

Perspec'vas Psicologicas en el Cuidado de la Diabetes

Pragma&c Clinical Trials

Mental Health, Substance Abuse & Primary Care: Bridging Gaps in Access

Designing and Delivering ACT Interven2ons for Individuals with Medical Condi2ons:

Session 13 Objec+ves MSDA Na+onal Medicaid and CHIP Oral Health Symposium June 24 th 26 th, 2012

Independence Well- being and Choice 2005, Our health, our care, our say 2006, Strong and Prosperous 2006

Oncology Care Model Overview

A Trial Implementa.on of a High Density Health Informa.on Exchange Standard: Are We Ready for Coordinated Care in High Impact Condi.ons?

Considera*ons when undergoing personal genotyping

Fall & Injury Preven/on: Demen/a + Hospitals = The Perfect Storm

Managing the U+liza+on of CT and MR Studies in an Era of Precer+fica+on

Evidence- based Catheter Associated Urinary Tract Infec8on CAUTI Preven8on. Effec%ve CAUTI Preven%on Saves Lives, Prevents Harm, and Reduces Costs

Blue Cross Blue Shield of Michigan Building a Statewide PCMH Program: Design, Evalua>on Methods, and Results

Prédire la récupéra1on rénale. Michaël DARMON Réanima1on polyvalente CHU de Saint- E1enne

Illinois Accountability Technical Advisory Committee (TAC) Academic Growth for Accountability

Caring for cancer patients with comorbidity. Chair: Associate Professor Diana Sarfa3

How does a heart surgeon prevent a heart a>ack?

Decision Support. HAP 752 Advanced Health Informa6on Systems. Janusz Wojtusiak, PhD George Mason University Spring 2014

Big Data Science and Analytics in Health and Biomedicine

Reducing Readmissions and Improving Outcomes at OhioHealth Mansfield Hospital:

Preven'ng AKI. Lessons from Contrast-associated AKI It s all about urine output

Pa#ern recogni,on and neuroimaging in psychiatry

Psychological outcomes of cri2cal illness for pa2ents and family members. Erin K. Kross, MD Summer Lung Day June 18, 2010

Medication Adherence Campaign Target Market Tracking Survey Results National Consumers League October 9, 2015

Upper Extremity Fractures and Secondary Fall Prevention: Opportunities to Improve Management and Outcomes Across Disciplines.

Tackling Tobacco Through Re-engineered Primary Care

Aggressive Medical Management with or without Angioplasty and Sten8ng for Symptoma8c Intracranial Atherosclero8c Stenosis: Long Term Results

Medical informa.on, flow and building rapid learning cancer knowledge centers

C-reac've protein-based TB screening

USING EVIDENCE FOR HEMATOLOGY LABORATORY PRACTICE. Alfonso Iorio McMaster University, Canada

F. Bochicchio The approach of the INRAP for preven8on and mi8ga8on and the new Direc8ve on BSS. Radon Protec8on Conf. Dresden, 2 3 Dec.

The Canadian Landscape of PaAent Reported Outcome and Experience Measures. Santana MJ, MPharm, PhD October 17, 2016, Amsterdam

The Availability of Homeopathic Medicinal Products (HMPs) in Europe with reference to the Matrix Report

Preparing Pre-health Professional Students & Advisors for the Mul8ple Mini-Interviews: Advanced Issues

Health Informa.cs. Lecture 9. Samantha Kleinberg

Resolving the PSA testing controversy. Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg

Documenting in the World of ICD-10 Capturing all your CCs and MCCs Crystal Coen, RN, MSN, FNP-BC NPSS Asheville, NC

Finding and Using Local Data for Suicide Preven7on

1/24/15. In pursuit of evidence- based prac8ce. Accessibility of Available Evidence. Today s Purpose BUT FIRST... Levels of Evidence (LOE)

Causal Inference from Complex Observa4onal Data. Samantha Kleinberg

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)

Genetic Tests and Genetic Counseling How to Analyze Your Own Genome

Hospital Transition Management. Barbara Wood, BSN, MBA

Effec&ve Messaging for Suicide Preven&on:

2015 Na(onal Medicaid and CHIP Oral Health Symposium. Integra(ng Oral and General Healthcare. Bruce Donoff, DMD, MD. Session #

Caveats and Recommendations for Use of Operational Electronic Health Record Data for Research and Quality Measurement

Suicide Care in Systems Framework: National Action Alliance Clinical Care and Intervention Task Force

An Introduc+on to Cancer Care at Kaiser Permanente Northwest. Phoebe E. Harvey, MD Chief, Hematology/Oncology Medical Director, Cancer Service Line

Population Health: The Path from Volume to Value

E. Scafato C. Gandin, L. Galluzzo, S. Ghirini, S. Martire, R. Scipione Istituto Superiore di Sanità, Italy

Maternal Mortality and HIV: Examining Research through a Programma;c Lens. Day 1 Recap

Global health; understanding, approach and major issues

Care of Diabe+c Pa+ents in the Hospital Se6ng

1. ATHENA Network, AVAC, and Salamander Trust with UN Women, undertook this mul>-stage review of the global status of access to an>retroviral therapy

Understanding. Design & Sta/s/cs. in Clinical Trials

Webinar Series Its All About the Interac0on Strategies for Pragma2c Organiza2on of Communica2on Systems PART 1

Sets, Logic, and Probability As Used in Decision Support Systems

For Objec*ve Causal Inference, Design Trumps Analysis. Donald B. Rubin Department of Sta*s*cs Harvard University 16 March 2012

Program: Module 2: Diagnosis and Investigation of HF and Practical Case Studies Treatment of Heart Failure and Practical Case Studies

Should Me*ormin be contraindicated in pa4ents with CKD? TAYLOR MCBRIDE UNIVERSITY OF TEXAS/HEB PGY-1 COMMUNITY PHARMACY RESIDENT

Maryland Patient Safety Center s Annual MEDSAFE Conference: Taking Charge of Your Medication Safety Challenges November 3, 2011 The Conference Center

The Data- Rich, Information- Driven Future of Healthcare

Ohio Medical Marijuana Control Program

Appendix Identification of Study Cohorts

The Digital Age of HP2020

Are We Ready for ASAM? Does the ASAM Level of Care Designa:ons Correspond to Clinical Judgment?

Medicare & Medicaid EHR Incentive Programs

Agenda. Clinical and Operational Considerations for Appropriate Telepsychiatry Best Prac/ces for Designing and Implemen/ng Telebehavioral Health

Clinical Research Project Design and Guidelines: Choosing a Research Ques8on

Information Technology-Driven Analytics: The Link Between Data Aggregation, Analytics and EHRs. Ronald A. Paulus, MD President and CEO June 27, 2011

Training + U*lizing Student Staff as Ac*ve Bystanders

Diabetes Self- management Educa4on and Support (DSME/S)

Objec0ves. Next Genera0on Biomarkers in Prostate Cancer. UBC Department of Urologic Sciences. Jennifer Locke, R2 January 28, 2015

SIMPATH Y. S*mula*ng Innova*on Management of Polypharmacy and Adherence in the Elderly Simpathy

Risk Assessment in IPC. Key Defini>ons. Risk Assessment in IPC

Stacie Fruth, PT, DHSc, OCS Michael Brickens, PT Tim Ellender, MD Jenny Gojmerac- Owens, NP Julie Welch, MD. Stacie Fruth, PT, DHSc, OCS

Polypharmacy Reviews in the real world

Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza

Transcription:

Development and Applica0on of Real- Time Clinical Predic0ve Models Ruben Amarasingham, MD, MBA Associate Professor, UT Southwestern Medical Center AHRQ- funded R24 UT Southwestern Center for Pa?ent- Centered Outcomes Research CEO, Parkland Center for Clinical Innova?on Date: Monday, December 1, 2015 Time: 12:00 1:00pm

Objec?ves Background: Predic?on and the Prac?ce of Medicine A Taxonomy for Predic?on and Decision Support Applica?on to Readmissions Further Considera?ons Q&A 2

What We Do in Medicine: Predic?on 1. What does this pa?ent have? 2. What will this pa?ent develop? 3. What will be the effect of a given therapy? 3

Predic?on in the Context of Modern Medicine Staggering increase in medical informa?on Increasing volume of decisions at mul?ple levels High fragmenta?on of care Increasing capacity for error 4

Glimmers of a New Age in Medicine Massive data capture Real-?me precision monitoring Vast computa?onal power Natural Language Processing Machine Learning 5

A Modified Taxonomy Term Predic?on Rule Decision Rule Decision Analysis Decision Support Prac?ce Guidelines e- Health Predic?ve Analysis Defini0on Provides diagnos?c or prognos?c probabili?es; does not recommend decision. Predic?on rule sufficiently validated to recommend decisions Quan?fies value of specified outcomes from published literature; health policy Designed to prevent errors when implemen?ng decisions already made Address several issues for pa?ents with a par?cular syndrome; ocen consensus based Technologies or socware systems that can autonomously employ and some?mes reengineer, modify, or update clinical risk predic?on models Reilly BM et al. Annals of Internal Medicine 2006;144:201-209 Amarasingham R et al. Health Affairs 2014 6

Clinical Applica?on of Predic?ve Analy?cs for Different Condi?ons and?meframe Hours 30 days 90 days Years Cardio- Pulmonary Arrest Sepsis Pa?ent Safety Event Surgical Complica?on Readmissions All- Cause AMI CHF PNA HIV Cirrhosis 7 Short- Term Diabe?c Complica?ons Chronic Kidney Disease Preventable DM Admissions

Predic?ng 30- Day Readmission in Heart Failure in Real- Time Heart failure readmissions are common, costly, and many are poten?ally preventable EMR- based readmission models are promising: Can tap many domains of risk Produce ac?onable intelligence usable in real-?me New domains of interest include: Socio- demographics, mental health/substance abuse, social disadvantage 8

Conceptual Model and Program Theory 9

Modeling HF Severity of Illness Model: Age, Albumin, T bili, CK, Crea?nine, Na, BUN, pco2, WBC, TN- I, Glucose, INR, BNP, ph, Temp, Pulse, Diastolic BP, Systolic BP (deriva?on=273, 034; valida?on=629,400) Tabak et al, Medical Care, 2007 10

Odds Ra?os for 30 Day Readmission for Final Model Variables Variable 11 Multivariate OR (95% CI) Tabak Mortality Score (composite) 1.52 (1.31-1.76) Single 1.44 (1.08-1.21) Male 1.37 (1.02-1.84) Number of Home Address Changes 1.13 (1.07-2.17) Medicare 1.59 (1.17-2.17) Residence in low SES census tract 1.38 (0.98-1.74) History of documented cocaine use 1.78 (1.17-2.72) History of missed clinic visit 1.35 (0.99-1.83) Used a health system pharmacy 0.72 (0.52-1.02) Number of prior inpatient admissions 1.17 (1.05-1.27) Presentation time (day or night) 1.38 (1.05-1.81) History of Depression or Anxiety 1.44 (1.00-2.07)

Performance of Electronic Heart Failure Model (N=1372, C- Stat 0.72) 70 60 Derivation Samples Validation Samples 51.65 50 45.68 40 30 26.93 26.0 20 10 8.77 12.22 14.27 16.08 17.94 19.98 0 Very Low Low Intermediate High Very High Predicted Readmission Risk Category 12 Amarasingham et al, Medical Care, 2010

From Predic?on to Ac?on: HF Interven?on Challenges & Solu?ons Iden?fy HF pa?ents in the first 24 hrs of admission Ocen no defini?ve admission diagnosis (SOB, edema, cough) Natural language processing to flag cases Too many pa?ents & too expensive to try to do everything on everyone Iden?fy those at highest risk to get enhanced suite of inpa?ent & outpa?ent interven?ons Provide electronic surveillance, coordina?on, & tracking of interven?on processes of care & outcomes 13

Readmission Preven?on Interven?on Workflow Admission Discharge 30 Days 90 Days 24 hours 7 days ID Risk List Orders 1 2 3 4 Inpatient Intervention 5 5 Outpatient Intervention Evaluation & Improvement 6 Electronic Medical Record Real- Time HL7 based interface EMR applica0on 14

Interven?on Results: 26% Rela?ve Reduc?on in Odds of Readmission Results Demonstrated: Concentrated care management efforts on ¼ of the pa?ents 26% rela?ve reduc?on in odds of readmission Absolute reduc?on of 5 readmissions per 100 index admissions Saved hospital $1 million 15

Compara?ve Effec?veness of Different Models for Predic?ng Readmissions 1. EMR- based v. administra?ve claims models 2. Develop & validate an all- cause, mul?- condi?on model 3. First- day v. full- stay models 4. Mul?- condi?on generic v. disease- specific models 5. Customizing models to individual hospitals, data systems, pa?ent popula?ons 16

Develop and Validate an All- Cause, Real- Time, Mul?- condi?on model 40 Derivation cohort Validation cohort 30 30.6 30.0 20 19.2 17.4 13.4 12.5 10 6.0 5.5 9.3 9.0 0 group 1 group 2 group 3 group 4 group 5 Predicted Risk Category Amarasingham et al. Under Review, 2014 17

EMR All Cause model versus CMS and LACE models 18

All- Cause 30- Day Readmission Model Full Hospital Stay versus First Day (n=16430) Predicted Risk, % C- sta?s?c (95% CI) Lowest Highest All- cause full- stay Deriva0on cohort 0.715 (0.704 0.727) 4 37 Valida0on cohort 0.689 (0.677 0.701) 4 37 All- cause 24- hour 0.667 (0.655 0.680) 6 32 Other models: LACE* 0.647 (0.635 0.660) 6 28 HOSPITAL model 0.636 (0.623 0.649) 7 27 CMS HWR 0.665 (0.652 0.678) 5 30 19

Other Considera?ons 1. Interven?ons for highest risk pa?ents 2. Considering clinical vs. social risk 3. Explana?on vs. Predic?on 4. Non- health care data sources 5. Changing EMR data models 6. Changing clinical interven?ons 7. Changing popula?ons 20

Larger Complexi?es of Predic?ve Modeling in Healthcare 21

Clinical Applica?on of Predic?ve Analy?cs for Different Condi?ons and?meframe Hours 30 days 90 days Years Cardio- Pulmonary Arrest Sepsis Pa?ent Safety Event Surgical Complica?on Readmissions All- Cause AMI CHF PNA HIV Cirrhosis 22 Short- Term Diabe?c Complica?ons Chronic Kidney Disease Preventable DM Admissions

Conclusions Predic?ve analy?cs are a promising way to help improve?meliness, safety and quality in health care; CHF model and interven?on are an example of successful implementa?on of predic?ve analy?cs in real- world setng; All Cause, Mul?- Condi?on Readmission Model has poten?al to have more significance for applica?on; Many challenges remain in methodology, applica?on and policy for electronic predic?ve analysis to thrive. 23

Ques?ons Contact Informa0on: Ruben Amarasingham ruben.amarasingham@phhs.org www.pccipieces.org 24